Baricitinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Baricitinib comprises 275 peer-reviewed publications across 15 journals, 42 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including COVID-19, Arthritis, Rheumatoid, Dermatitis, Atopic, and Arthritis. Most recent publication: Cytokine-Driven Janus Kinase Signal Transducer and Activator of Transcription Pathway Hyperactivity Predicts Disease Severity in Pediatric FSGS., Kidney360, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.
    Waibel M, Wentworth JM, So M, et al. · N Engl J Med · 2023
    PubMed: PMID 38055252 · NCT04774224 (BANDIT) · Diabetes Mellitus, Type 1
  2. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022
    PubMed: PMID 33933206 · NCT04381936 (RECOVERY) · COVID-19
  3. Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Infect Dis · 2025
    PubMed: PMID 40886716 · NCT04381936 (RECOVERY) · COVID-19
  4. Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Infect Dis · 2025
    PubMed: PMID 40383127 · NCT04381936 (RECOVERY) · COVID-19
  5. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Diabetes Endocrinol · 2023
    PubMed: PMID 37865101 · NCT04381936 (RECOVERY) · COVID-19
  6. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group. Electronic address: [email protected], RECOVERY Collaborative Group · Lancet · 2023
    PubMed: PMID 37060915 · NCT04381936 (RECOVERY) · COVID-19
  7. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022
    PubMed: PMID 34000257 · NCT04381936 (RECOVERY) · COVID-19
  8. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Respir Med · 2022
    PubMed: PMID 34672950 · NCT04381936 (RECOVERY) · COVID-19

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT01710358
RA-BEAM
Arthritis, RheumatoidPercentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)
Week 12
Adalimumab61.2 percentage of participants
Baricitinib69.6 percentage of participants
Placebo40.2 percentage of participants
NCT01711359
RA-BEGIN
Arthritis, RheumatoidPercentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)
Week 24
Baricitinib73.0 Percent of participants
Baricitinib76.7 Percent of participants
Baricitinib + MTX78.1 Percent of participants
Baricitinib + MTX72.6 Percent of participants
Methotrexate61.9 Percent of participants
Methotrexate55.7 Percent of participants
NCT01721044
RA-BEACON
Arthritis, RheumatoidPercentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg
Week 12
Baricitinib 4 mg55.4 Percentage of Participants
Placebo27.3 Percentage of Participants
NCT01721057
RA-BUILD
Arthritis, RheumatoidPercentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)
Week 12
Baricitinib 2 mg65.9 percentage of participants
Baricitinib 4 mg61.7 percentage of participants
Placebo39.5 percentage of participants
NCT01885078
RA-BEYOND
Arthritis, RheumatoidNumber of Participants Who Experienced Adverse Events (AEs) or Serious AE
Baseline through 84 Months
2 mg Baricitinib112 participants
2 mg Baricitinib234 participants
2 mg Baricitinib Step-down270 participants
2 mg Baricitinib Step-down164 participants
4 mg Baricitinib1532 participants
4 mg Baricitinib517 participants
4 mg Baricitinib Step-down178 participants
4 mg Baricitinib Step-down315 participants
NCT02265705Arthritis, RheumatoidPercentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20)
Week 12
Baricitinib58.6 percentage of participants
Placebo28.3 percentage of participants
NCT03334396
BREEZE-AD1
Dermatitis, AtopicPercentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2 mg, or 4 mg Baricitinib)
16 Weeks
2 mg Baricitinib11.4 percentage of participants
4 mg Baricitinib16.8 percentage of participants
Placebo4.8 percentage of participants
NCT03334422
BREEZE-AD2
Dermatitis, AtopicPercentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement (Placebo, 2mg and 4mg Baricitinib)
16 Weeks
2mg Baricitinib10.6 percentage of participants
4mg Baricitinib13.8 percentage of participants
Placebo4.5 percentage of participants
NCT03334435
BREEZE-AD3
Dermatitis, AtopicResponder and Partial Responders (RPR): Percentage of Participants From Monotherapy Studies (JAHL, JAHM) Who Achieved a Response of Investigator's Global Assessment (IGA) 0 or 1
Weeks 16, 36 and 52
RPR-Bari 1-mg35.6 Percentage of participants
RPR-Bari 1-mg46.7 Percentage of participants
RPR-Bari 1-mg31.1 Percentage of participants
RPR-Bari 2-mg50.0 Percentage of participants
RPR-Bari 2-mg63.0 Percentage of participants
RPR-Bari 2-mg59.3 Percentage of participants
RPR-Bari 4-mg48.6 Percentage of participants
RPR-Bari 4-mg40.0 Percentage of participants
RPR-Bari 4-mg37.1 Percentage of participants
RPR-Placebo28.8 Percentage of participants
RPR-Placebo36.5 Percentage of participants
RPR-Placebo23.1 Percentage of participants
NCT03334435
BREEZE-AD3
Dermatitis, AtopicRPR: Percentage of Participants From Combination Therapy Study (JAIY) Who Achieved a Response of IGA 0 or 1
Weeks 16, 36, and 52
RPR-Bari 2-mg30.2 Percentage of participants
RPR-Bari 2-mg24.5 Percentage of participants
RPR-Bari 2-mg45.3 Percentage of participants
RPR-Bari 4-mg31.7 Percentage of participants
RPR-Bari 4-mg31.7 Percentage of participants
RPR-Bari 4-mg30.2 Percentage of participants
RPR-Placebo29.4 Percentage of participants
RPR-Placebo41.2 Percentage of participants
RPR-Placebo47.1 Percentage of participants
NCT03428100
BREEZE-AD4
Dermatitis, AtopicPercentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib)
Week 16
2 mg Baricitinib27.6 percentage of participants
4 mg Baricitinib31.5 percentage of participants
Placebo17.2 percentage of participants
NCT03435081
BREEZE-AD5
Dermatitis, AtopicPercentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitinib)
Week 16
2 mg Baricitinib29.5 percentage of participants
Placebo8.2 percentage of participants
NCT03559270
BREEZE-AD6
Dermatitis, AtopicPercentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75)
Week 16
Baricitinib 1-mg/Baricitinib 2-mg40.3 percentage of participants
Baricitinib 2-mg Open-Label Addendum50.0 percentage of participants
Baricitinib 2-mg/Baricitinib 2-mg45.4 percentage of participants
Placebo/Baricitinib 2-mg59.0 percentage of participants
NCT03570749
BRAVE-AA1
Alopecia AreataPercent Change From Baseline in SALT Score - Phase 3 Open-Label Addendum
Baseline, Week 52
4 mg Baricitinib Phase 3 Open-Label Addendum-40.44 percent change (±33.182 Standard Deviation)
NCT03570749
BRAVE-AA1
Alopecia AreataPercentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20 - Phase 3
Week 36
2 mg Baricitinib Phase 321.7 percentage of participants
4 mg Baricitinib Phase 335.2 percentage of participants
Placebo Phase 35.3 percentage of participants
NCT03616912
SLE-BRAVE I
Lupus Erythematosus, SystemicPercentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib)
Week 52
4 mg Baricitinib56.7 percentage of participants
Placebo45.9 percentage of participants
NCT03616964
BRAVE II
Lupus Erythematosus, SystemicPercentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib)
Week 52
4 mg Baricitinib47.1 percentage of participants
Placebo45.6 percentage of participants
NCT03733301
BREEZE-AD7
Dermatitis, AtopicPercentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement
Week 16
2 mg Baricitinib23.9 percentage of participants
4 mg Baricitinib30.6 percentage of participants
Placebo14.7 percentage of participants
NCT03773978
JUVE-BASIS
ArthritisTime to Disease Flare
Week 12 to Week 44
BaricitinibNA Weeks
Placebo27.14 Weeks
NCT03843125
SLE-BRAVE-X
Lupus Erythematosus, SystemicPercentage of Participants With Adverse Events of Special Interest (AESIs)
Week 134
2 mg Baricitinib0.3 Percentage of participants
2 mg Baricitinib38.4 Percentage of participants
2 mg Baricitinib0 Percentage of participants
2 mg Baricitinib0.3 Percentage of participants
2 mg Baricitinib0.3 Percentage of participants
2 mg Baricitinib0.5 Percentage of participants
2 mg Baricitinib3.6 Percentage of participants
2 mg Baricitinib3.6 Percentage of participants
2 mg Baricitinib0.3 Percentage of participants
2 mg Baricitinib1.3 Percentage of participants
4 mg Baricitinib1.6 Percentage of participants
4 mg Baricitinib42.1 Percentage of participants
4 mg Baricitinib0.8 Percentage of participants
4 mg Baricitinib1.1 Percentage of participants
4 mg Baricitinib0.8 Percentage of participants
4 mg Baricitinib0.8 Percentage of participants
4 mg Baricitinib4.2 Percentage of participants
4 mg Baricitinib4.2 Percentage of participants
4 mg Baricitinib0.8 Percentage of participants
4 mg Baricitinib0.3 Percentage of participants
Placebo to 2 mg Baricitinib1.6 Percentage of participants
Placebo to 2 mg Baricitinib0.5 Percentage of participants
Placebo to 2 mg Baricitinib0 Percentage of participants
Placebo to 2 mg Baricitinib36.5 Percentage of participants
Placebo to 2 mg Baricitinib1.1 Percentage of participants
Placebo to 2 mg Baricitinib5.8 Percentage of participants
Placebo to 2 mg Baricitinib5.8 Percentage of participants
Placebo to 2 mg Baricitinib0.5 Percentage of participants
Placebo to 2 mg Baricitinib0.5 Percentage of participants
Placebo to 2 mg Baricitinib0 Percentage of participants
Placebo to 4 mg Baricitinib0 Percentage of participants
Placebo to 4 mg Baricitinib0.5 Percentage of participants
Placebo to 4 mg Baricitinib3.1 Percentage of participants
Placebo to 4 mg Baricitinib0.5 Percentage of participants
Placebo to 4 mg Baricitinib0.5 Percentage of participants
Placebo to 4 mg Baricitinib3.1 Percentage of participants
Placebo to 4 mg Baricitinib0 Percentage of participants
Placebo to 4 mg Baricitinib35.1 Percentage of participants
Placebo to 4 mg Baricitinib0.5 Percentage of participants
Placebo to 4 mg Baricitinib0 Percentage of participants
NCT03843125
SLE-BRAVE-X
Lupus Erythematosus, SystemicPercentage of Participants With Permanent Investigational Product Discontinuations
Week 134
2 mg Baricitinib5.2 Percentage of Participants
4 mg Baricitinib5.8 Percentage of Participants
Placebo to 2 mg Baricitinib4.2 Percentage of Participants
Placebo to 4 mg Baricitinib5.8 Percentage of Participants
NCT03843125
SLE-BRAVE-X
Lupus Erythematosus, SystemicPercentage of Participants With Serious Adverse Events (SAEs)
Week 134
2 mg Baricitinib11.1 Percentage of Participants
4 mg Baricitinib13.5 Percentage of Participants
Placebo to 2 mg Baricitinib11.1 Percentage of Participants
Placebo to 4 mg Baricitinib11.5 Percentage of Participants
NCT03843125
SLE-BRAVE-X
Lupus Erythematosus, SystemicPercentage of Participants With Temporary Investigational Product Interruptions
Week 134
2 mg Baricitinib19.1 Percentage of Participants
4 mg Baricitinib24.6 Percentage of Participants
Placebo to 2 mg Baricitinib18.5 Percentage of Participants
Placebo to 4 mg Baricitinib23.6 Percentage of Participants
NCT03843125
SLE-BRAVE-X
Lupus Erythematosus, SystemicPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Week 134
2 mg Baricitinib61.9 Percentage of Participants
4 mg Baricitinib68.8 Percentage of Participants
Placebo to 2 mg Baricitinib65.1 Percentage of Participants
Placebo to 4 mg Baricitinib64.4 Percentage of Participants
NCT03899259
BRAVE-AA2
Alopecia AreataPercentage of Participants Achieving Severity of Alopecia Tool (SALT) ≤ 20
Week 36
2 mg Baricitinib17.3 percentage of participants
4 mg Baricitinib32.5 percentage of participants
Placebo2.6 percentage of participants
NCT03952559
BREEZE-AD-PEDS
Dermatitis, AtopicOpen Label Pop PK: Area Under the Concentration-Time Curve for Dosing Interval at Steady State (AUCtau,ss) of LY3009104
Predose; 0.25 h; 0.5 h; 1 h; 2-4 h; 4 h and 4-6 h post dose
Baricitinib Open Label High Dose 10 to <18290 hour*nanogram per milliliter (h*ng/mL) (±44 Geometric Coefficient of Variation)
Baricitinib Open Label High Dose 2 to <6251 hour*nanogram per milliliter (h*ng/mL) (±18 Geometric Coefficient of Variation)
Baricitinib Open Label High Dose 6 to <10178 hour*nanogram per milliliter (h*ng/mL) (±18 Geometric Coefficient of Variation)
NCT03952559
BREEZE-AD-PEDS
Dermatitis, AtopicOpen Label Population Pharmacokinetics (Pop PK): Maximum Observed Drug Concentration at Steady State (Cmax,ss) of LY3009104
Predose; 0.25 hours (h); 0.5 h; 1 h; 2-4 h; 4 h and 4-6 h post dose
Baricitinib Open Label High Dose 10 to <1850.6 nanogram per milliliter (ng/mL) (±29 Geometric Coefficient of Variation)
Baricitinib Open Label High Dose 2 to <663.2 nanogram per milliliter (ng/mL) (±30 Geometric Coefficient of Variation)
Baricitinib Open Label High Dose 6 to <1040.1 nanogram per milliliter (ng/mL) (±32 Geometric Coefficient of Variation)
NCT03952559
BREEZE-AD-PEDS
Dermatitis, AtopicPercentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥2 Point Improvement
Week 16
Baricitinib Double-blind High Dose41.7 Percentage of participants
Baricitinib Double-blind Low Dose18.2 Percentage of participants
Baricitinib Double-blind Medium Dose25.8 Percentage of participants
Placebo Double-blind16.4 Percentage of participants
NCT04088409UveitisPart A: Percentage of Responders for Baricitinib at Week 24
Week 24
Baricitinib33.3 Percentage of participants
NCT04401579COVID-19Time to Recovery
Day 1 through Day 29
Remdesivir Plus Baricitinib7.0 Days
Remdesivir Plus Placebo8.0 Days
NCT04401579COVID-19Time to Recovery by Ethnicity
Day 1 through Day 29
Remdesivir Plus Baricitinib7.0 Days
Remdesivir Plus Baricitinib7.0 Days
Remdesivir Plus Placebo9.0 Days
Remdesivir Plus Placebo7.0 Days
NCT04401579COVID-19Time to Recovery by Race
Day 1 through Day 29
Remdesivir Plus Baricitinib10 Days
Remdesivir Plus Baricitinib7.0 Days
Remdesivir Plus Baricitinib7.0 Days
Remdesivir Plus Baricitinib7.0 Days
Remdesivir Plus Placebo8.0 Days
Remdesivir Plus Placebo7.0 Days
Remdesivir Plus Placebo6.0 Days
Remdesivir Plus Placebo10.0 Days
NCT04401579COVID-19Time to Recovery by Sex
Day 1 through Day 29
Remdesivir Plus Baricitinib7.0 Days
Remdesivir Plus Baricitinib7.0 Days
Remdesivir Plus Placebo9.0 Days
Remdesivir Plus Placebo7.0 Days
NCT04421027
COV-BARRIER
COVID-19Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO] Population 2
Day 1 to Day 28
Baricitinib + SOC28.9 percentage of participants
Placebo + SOC27.1 percentage of participants
NCT04421027
COV-BARRIER
COVID-19Percentage of Participants Who Die or Require Non-Invasive Ventilation/High-Flow Oxygen or Invasive Mechanical Ventilation (Including Extracorporeal Membrane Oxygenation [ECMO])
Day 1 to Day 28
Baricitinib + SOC27.8 percentage of participants
Placebo + SOC30.5 percentage of participants
NCT04517253Aicardi-Goutieres syndromeChange From Baseline in Mean Daily Diary Scores in Participants With AGS (Primary Treatment Period)
Baseline, 32 weeks
Aicardi-Goutières Syndrome (AGS)-0.045 score on a scale (±0.164 Standard Deviation)
NCT04517253Aicardi-Goutieres syndromeChange From Baseline in Mean Daily Diary Scores in Participants With CANDLE (Primary Treatment Period)
Baseline, 20 weeks
CANDLE-0.217 score on a scale (±0.586 Standard Deviation)
NCT04517253Aicardi-Goutieres syndromeChange From Baseline in Mean Daily Diary Scores in Participants With SAVI (Primary Treatment Period)
Baseline, 32 weeks
SAVI-0.23 score on a scale (±0.238 Standard Deviation)
NCT04640168COVID-19The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)
Day 1 through Day 29
Remdesivir Plus Baricitinib0.87 Proportion of participants
Remdesivir Plus Dexamethasone0.88 Proportion of participants
NCT04640168COVID-19The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Ethnicity
Day 1 through Day 29
Remdesivir Plus Baricitinib0.87 Proportion of participants
Remdesivir Plus Baricitinib0.88 Proportion of participants
Remdesivir Plus Dexamethasone0.87 Proportion of participants
Remdesivir Plus Dexamethasone0.87 Proportion of participants
NCT04640168COVID-19The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Race
Day 1 through Day 29
Remdesivir Plus Baricitinib0.87 Proportion of participants
Remdesivir Plus Baricitinib0.91 Proportion of participants
Remdesivir Plus Baricitinib0.76 Proportion of participants
Remdesivir Plus Baricitinib0.87 Proportion of participants
Remdesivir Plus Dexamethasone0.86 Proportion of participants
Remdesivir Plus Dexamethasone0.88 Proportion of participants
Remdesivir Plus Dexamethasone0.88 Proportion of participants
Remdesivir Plus Dexamethasone0.89 Proportion of participants
NCT04640168COVID-19The Proportion of Participants Not Meeting Criteria for One of the Following Two Ordinal Scale Categories at Any Time: 8) Death; 7) Hospitalized, on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO) by Sex
Day 1 through Day 29
Remdesivir Plus Baricitinib0.86 Proportion of participants
Remdesivir Plus Baricitinib0.89 Proportion of participants
Remdesivir Plus Dexamethasone0.87 Proportion of participants
Remdesivir Plus Dexamethasone0.88 Proportion of participants

Publications by year

1989–2026: 275 publications.

1989
1
1994
1
2001
1
2002
4
2003
2
2006
5
2007
1
2008
2
2009
6
2011
2
2012
1
2013
3
2014
5
2015
3
2016
3
2017
9
2018
8
2019
15
2020
37
2021
48
2022
43
2023
34
2024
21
2025
16
2026
4

Publications by indication

COVID-19 (85)

  • Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    Lancet Infect Dis · 2025 · PMID 40886716 · NCT04381936
  • Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    Lancet Infect Dis · 2025 · PMID 40383127 · NCT04381936
  • Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.
    Intensive Care Med · 2025 · PMID 40261382 · NCT02735707
  • Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
    EClinicalMedicine · 2025 · PMID 40036152 · NCT04381936
  • Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial.
    Thorax · 2025 · PMID 40360262 · NCT02735707

Arthritis, Rheumatoid (37)

  • Validation of Boolean 2.0 criteria for remission and quality of life prediction in Korean patients with rheumatoid arthritis receiving targeted therapy.
    Rheumatology (Oxford) · 2026 · PMID 41025512 · NCT04449224
  • Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.
    RMD Open · 2025 · PMID 28405473 · NCT01721057
  • Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study.
    Ther Adv Musculoskelet Dis · 2024 · PMID 33959198 · NCT02265705
  • Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study.
    Rheumatol Ther · 2024 · PMID 34028703 · NCT01721044
  • Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain.
    Clinicoecon Outcomes Res · 2024 · PMID 31239736 · NCT01710358

Dermatitis, Atopic (31)

  • Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years.
    J Dermatolog Treat · 2024 · PMID 39522957 · NCT03952559
  • Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials.
    Dermatitis · 2023 · PMID 36749121 · NCT03559270
  • Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.
    J Dermatolog Treat · 2023 · PMID 36912484 · NCT03334435
  • Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
    Br J Dermatol · 2023 · PMID 36763879 · NCT03334435
  • Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
    Dermatol Ther (Heidelb) · 2022 · PMID 34275122 · NCT03733301

Arthritis (19)

  • Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.
    Lancet Rheumatol · 2025 · PMID 40915298 · NCT03773978
  • Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis.
    Ann Rheum Dis · 2025 · PMID 35613842 · NCT06768294
  • Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level.
    Lancet Rheumatol · 2024 · PMID 38251579 · NCT06768294
  • The cardiovascular risk of JAK inhibitors in treating rheumatic diseases.
    Int J Rheum Dis · 2024 · PMID 39187987 · NCT06768294
  • Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis.
    Lancet Rheumatol · 2024 · PMID 38273598 · NCT06768294

Adenoma, Liver Cell (18)

  • Evaluation of liver tumour response by imaging.
    JHEP Rep · 2023 · PMID 32514496 · NCT06490757
  • Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation.
    Hepatology · 2023 · PMID 35980227 · NCT06490757
  • Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    N Engl J Med · 2022 · PMID 35081280 · NCT06490757
  • Benign liver tumours: understanding molecular physiology to adapt clinical management.
    Nat Rev Gastroenterol Hepatol · 2022 · PMID 35835851 · NCT06490757
  • Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course.
    Liver Int · 2021 · PMID 34155783 · NCT06490757

Alopecia Areata (14)

  • Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment.
    Am J Clin Dermatol · 2025 · PMID 40214720 · NCT03899259
  • Biological Functions of RBP4 and Its Relevance for Human Diseases.
    Front Physiol · 2025 · PMID 33790810 · NCT06545110
  • Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata.
    Dermatol Ther (Heidelb) · 2024 · PMID 37991697 · NCT03570749
  • Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.
    JAMA Dermatol · 2024 · PMID 39141364 · NCT03570749
  • Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib.
    Dermatol Ther (Heidelb) · 2024 · PMID 38904749 · NCT03899259

Publications by journal

Trial-results highlights

For rheumatoid arthritis, several studies investigated the percentage of participants achieving American College of Rheumatology 20% Improvement (ACR20). In the NCT01710358 (RA-BEAM) study, at Week 12, 69.6 percentage of participants in the Baricitinib arm achieved ACR20, compared to 61.2 percentage of participants in the Adalimumab arm and 40.2 percentage of participants in the Placebo arm. The NCT01711359 (RA-BEGIN) study reported ACR20 at Week 24 for several arms:

  • Baricitinib: 73.0 Percent of participants and 76.7 Percent of participants
  • Baricitinib + MTX: 78.1 Percent of participants and 72.6 Percent of participants
  • Methotrexate: 61.9 Percent of participants and 55.7 Percent of participants

Other studies also assessed ACR20 at Week 12. In NCT01721044 (RA-BEACON), 55.4 Percentage of Participants in the Baricitinib 4 mg arm achieved ACR20, versus 27.3 Percentage of Participants in the Placebo arm. For NCT01721057 (RA-BUILD), 65.9 percentage of participants in the Baricitinib 2 mg arm and 61.7 percentage of participants in the Baricitinib 4 mg arm achieved ACR20, compared to 39.5 percentage of participants in the Placebo arm. In NCT02265705, 58.6 percentage of participants in the Baricitinib arm achieved ACR20, versus 28.3 percentage of participants in the Placebo arm.

Regarding adverse events in rheumatoid arthritis, the NCT01885078 (RA-BEYOND) study tracked the number of participants who experienced adverse events or serious adverse events from baseline through 84 months. In this study, 112 participants and 234 participants were reported in the 2 mg Baricitinib arm. The 2 mg Baricitinib Step-down arm reported 270 participants and 164 participants. For the 4 mg Baricitinib arm, 1532 participants and 517 participants experienced adverse events or serious adverse events. For atopic dermatitis, two studies, NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2), assessed the percentage of participants achieving an Investigator's Global Assessment (IGA) of 0 or 1 with a ≥ 2 point improvement at 16 Weeks. In NCT03334396 (BREEZE-AD1), 11.4 percentage of participants in the 2 mg Baricitinib arm and 16.8 percentage of participants in the 4 mg Baricitinib arm achieved this endpoint, compared to 4.8 percentage of participants in the Placebo arm. Similarly, in NCT03334422 (BREEZE-AD2), 10.6 percentage of participants in the 2mg Baricitinib arm and 13.8 percentage of participants in the 4mg Baricitinib arm achieved this endpoint, versus 4.5 percentage of participants in the Placebo arm.

All values are sourced from primary registry reporting, and individual published papers should be consulted for clinical decisions.

All Baricitinib publications (275)

2026 (4 papers)

  1. Cytokine-Driven Janus Kinase Signal Transducer and Activator of Transcription Pathway Hyperactivity Predicts Disease Severity in Pediatric FSGS.
    Shen CL, Richardson A, Martin-Fernandez M, et al. · Kidney360 · 2026 · Derived
    PubMed: PMID 41236849 · NCT05237388 (JUSTICE) · Glomerulosclerosis, Focal Segmental
  2. Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease.
    Hu S, Lee K, He JC, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41805697 · NCT01683409 · Diabetic Nephropathies
  3. Validation of Boolean 2.0 criteria for remission and quality of life prediction in Korean patients with rheumatoid arthritis receiving targeted therapy.
    Cho SK, Choi SR, Nam E, et al. · Rheumatology (Oxford) · 2026 · Derived
    PubMed: PMID 41025512 · NCT04449224 · Arthritis, Rheumatoid
  4. Hybrid Community-Electronic Health Record Approaches to Apolipoprotein L1 Kidney Disease Screening and Clinical Trials among Black Individuals.
    Barrett N, Odera JO, Bethea K, et al. · J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 41774497 · NCT05237388 (JUSTICE) · Glomerulosclerosis, Focal Segmental

2025 (16 papers)

  1. Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Infect Dis · 2025 · Trial result
    PubMed: PMID 40886716 · NCT04381936 (RECOVERY) · COVID-19
  2. Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Infect Dis · 2025 · Trial result
    PubMed: PMID 40383127 · NCT04381936 (RECOVERY) · COVID-19
  3. Repurposing the composite assessment of index lesion severity scoring system in cutaneous lichen planus.
    Zhang N, Stockard AL, Leibovit-Reiben Z, et al. · Arch Dermatol Res · 2025 · Derived
    PubMed: PMID 39951132 · NCT05188521 · Lichen Planus
  4. Clinical outcomes of baricitinib in patients with systemic lupus erythematosus: Pooled analysis of SLE-BRAVE-I and SLE-BRAVE-II trials.
    Yin J, Hou Y, Wang C, et al. · PLoS One · 2025 · Derived
    PubMed: PMID 40305472 · NCT03616912 (SLE-BRAVE I) · Lupus Erythematosus, Systemic
  5. Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial.
    Seneschal J, Guyon M, Merhi R, et al. · JAMA Dermatol · 2025 · Derived
    PubMed: PMID 39841460 · NCT04822584 (BARVIT) · Vitiligo
  6. Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial.
    Saraux A, Carvajal Alegria G, Dernis E, et al. · Lancet Rheumatol · 2025 · Derived
    PubMed: PMID 39818228 · NCT04027101 (BACHELOR)
  7. Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia : The REMAP-CAP Corticosteroid Domain Randomized Clinical Trial.
    REMAP-CAP Investigators, Angus DC · Intensive Care Med · 2025 · Derived
    PubMed: PMID 40261382 · NCT02735707 (REMAP-CAP) · COVID-19
  8. Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · EClinicalMedicine · 2025 · Derived
    PubMed: PMID 40036152 · NCT04381936 (RECOVERY) · COVID-19
  9. Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial.
    Li J, Xia W, Ji H, et al. · Rheumatology (Oxford) · 2025 · Derived
    PubMed: PMID 40411764 · NCT06662721 · Takayasu Arteritis
  10. Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.
    Krishnan V, Keller SY, Chew C, et al. · Lancet Rheumatol · 2025 · Derived
    PubMed: PMID 40915298 · NCT03773978 (JUVE-BASIS) · Arthritis
  11. Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment.
    King B, Mostaghimi A, Shimomura Y, et al. · Am J Clin Dermatol · 2025 · Derived
    PubMed: PMID 40214720 · NCT03899259 (BRAVE-AA2) · Alopecia Areata
  12. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis.
    Emery P, Blanco R, Maldonado Cocco J, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 28405473 · NCT01721057 (RA-BUILD) · Arthritis, Rheumatoid
  13. Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus.
    Dörner T, Tanaka Y, Dow ER, et al. · Ann Rheum Dis · 2025 · Derived
    PubMed: PMID 35609978 · NCT02708095 · Lupus Erythematosus, Systemic
  14. Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial.
    Derde L, Gordon AC, Mouncey PR, et al. · Thorax · 2025 · Derived
    PubMed: PMID 40360262 · NCT02735707 (REMAP-CAP) · COVID-19
  15. Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis.
    Tedeschi SK, Huang W, Yoshida K, et al. · Ann Rheum Dis · 2025 · Background
    PubMed: PMID 35613842 · NCT06768294 (BAPTIST) · Arthritis
  16. Biological Functions of RBP4 and Its Relevance for Human Diseases.
    Steinhoff JS, Lass A, Schupp M, et al. · Front Physiol · 2025 · Background
    PubMed: PMID 33790810 · NCT06545110 · Alopecia Areata

2024 (21 papers)

  1. Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group, Horby PW, Peto L, et al. · Nat Commun · 2024 · Trial result
    PubMed: PMID 38296965 · NCT04381936 (RECOVERY) · COVID-19
  2. Safety and efficacy of baricitinib in steroid-resistant or relapsed immune thrombocytopenia: An open-label pilot study.
    Zhao P, An ZY, Fu HX, et al. · Am J Hematol · 2024 · Derived
    PubMed: PMID 38980207 · NCT05446831 (BAITP) · Purpura, Thrombocytopenic, Idiopathic
  3. Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study.
    Yang Y, Xu J, Xu J, et al. · Ther Adv Musculoskelet Dis · 2024 · Derived
    PubMed: PMID 33959198 · NCT02265705 · Arthritis, Rheumatoid
  4. Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years.
    Wollenberg A, Ikeda M, Chu CY, et al. · J Dermatolog Treat · 2024 · Derived
    PubMed: PMID 39522957 · NCT03952559 (BREEZE-AD-PEDS) · Dermatitis, Atopic
  5. Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study.
    Wells AF, Jia B, Xie L, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 34028703 · NCT01721044 (RA-BEACON) · Arthritis, Rheumatoid
  6. Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata.
    Senna MM, Kwon O, Piraccini BM, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 37991697 · NCT03570749 (BRAVE-AA1) · Alopecia Areata
  7. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain.
    Schlueter M, Finn E, Díaz S, et al. · Clinicoecon Outcomes Res · 2024 · Derived
    PubMed: PMID 31239736 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  8. Simvastatin in Critically Ill Patients with Covid-19.
    REMAP-CAP Investigators, Hills TE, Lorenzi E, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 37888913 · NCT02735707 (REMAP-CAP) · COVID-19
  9. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Child Adolesc Health · 2024 · Derived
    PubMed: PMID 38272046 · NCT04381936 (RECOVERY) · COVID-19
  10. Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.
    Pessoa-Amorim G, Goldacre R, Crichton C, et al. · Trials · 2024 · Derived
    PubMed: PMID 38951929 · NCT04381936 (RECOVERY) · COVID-19
  11. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
    Paules CI, Wang J, Tomashek KM, et al. · Ann Intern Med · 2024 · Derived
    PubMed: PMID 38408357 · NCT04401579 · COVID-19
  12. Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial.
    King B, Ko J, Kwon O, et al. · JAMA Dermatol · 2024 · Derived
    PubMed: PMID 39141364 · NCT03570749 (BRAVE-AA1) · Alopecia Areata
  13. Oral Baricitinib in the Treatment of Cutaneous Lichen Planus.
    Hwang A, Kechter J, Do T, et al. · medRxiv · 2024 · Derived
    PubMed: PMID 38260663 · NCT05188521 · Lichen Planus
  14. Improvement in Measures of Quality of Life and Symptoms of Anxiety and Depression in Patients with Severe Alopecia Areata Achieving Sustained Scalp Hair Regrowth with Baricitinib.
    Craiglow B, Lee YW, Vañó-Galván S, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38904749 · NCT03899259 (BRAVE-AA2) · Alopecia Areata
  15. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study.
    Caporali R, Taylor PC, Aletaha D, et al. · Rheumatology (Oxford) · 2024 · Derived
    PubMed: PMID 38258434 · NCT01885078 (RA-BEYOND) · Arthritis, Rheumatoid
  16. A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience.
    Taylor PC, Laedermann C, Alten R, et al. · J Clin Med · 2024 · Background
    PubMed: PMID 37445562 · NCT06439615 (BLISS) · Pneumonia
  17. Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level.
    Sirotti S, Terslev L, Filippucci E, et al. · Lancet Rheumatol · 2024 · Background
    PubMed: PMID 38251579 · NCT06768294 (BAPTIST) · Arthritis
  18. Contemporary management of aneurysmal subarachnoid haemorrhage. An update for the intensivist.
    Robba C, Busl KM, Claassen J, et al. · Intensive Care Med · 2024 · Background
    PubMed: PMID 38598130 · NCT06439615 (BLISS) · Pneumonia
  19. The cardiovascular risk of JAK inhibitors in treating rheumatic diseases.
    Kwan A, Ingrid E, Jiang M, et al. · Int J Rheum Dis · 2024 · Background
    PubMed: PMID 39187987 · NCT06768294 (BAPTIST) · Arthritis
  20. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis.
    Genovese MC, Smolen JS, Takeuchi T, et al. · Lancet Rheumatol · 2024 · Background
    PubMed: PMID 38273598 · NCT06768294 (BAPTIST) · Arthritis
  21. Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis.
    Damart J, Filippou G, Andrès M, et al. · Rheumatology (Oxford) · 2024 · Background
    PubMed: PMID 37216917 · NCT06768294 (BAPTIST) · Arthritis

2023 (34 papers)

  1. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis.
    Wijaya I, Andhika R, Huang I, et al. · Clin Epidemiol Glob Health · 2023 · Trial result
    PubMed: PMID 33969237 · NCT04970719 · COVID-19
  2. Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.
    Waibel M, Wentworth JM, So M, et al. · N Engl J Med · 2023 · Trial result
    PubMed: PMID 38055252 · NCT04774224 (BANDIT) · Diabetes Mellitus, Type 1
  3. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
    Trøseid M, Arribas JR, Assoumou L, et al. · Crit Care · 2023 · Trial result
    PubMed: PMID 36627655 · NCT04891133 (Bari-SolidAct) · COVID-19
  4. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Diabetes Endocrinol · 2023 · Trial result
    PubMed: PMID 37865101 · NCT04381936 (RECOVERY) · COVID-19
  5. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group. Electronic address: [email protected], RECOVERY Collaborative Group · Lancet · 2023 · Trial result
    PubMed: PMID 37060915 · NCT04381936 (RECOVERY) · COVID-19
  6. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
    Writing Committee for the REMAP-CAP Investigators, Lawler PR, Derde LPG, et al. · JAMA · 2023 · Derived
    PubMed: PMID 37039790 · NCT02735707 (REMAP-CAP) · COVID-19
  7. Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials.
    Wollenberg A, Kircik L, Simpson E, et al. · Dermatitis · 2023 · Derived
    PubMed: PMID 36749121 · NCT03559270 (BREEZE-AD6) · Dermatitis, Atopic
  8. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.
    Thyssen JP, Werfel T, Barbarot S, et al. · J Dermatolog Treat · 2023 · Derived
    PubMed: PMID 36912484 · NCT03334435 (BREEZE-AD3) · Dermatitis, Atopic
  9. Baricitinib Improves Bone Properties and Biomechanics in Patients With Rheumatoid Arthritis: Results of the Prospective Interventional BARE BONE Trial.
    Simon D, Minopoulou I, Kemenes S, et al. · Arthritis Rheumatol · 2023 · Derived
    PubMed: PMID 37229650 · NCT03701789 (BAREBONE) · Arthritis, Rheumatoid
  10. Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
    Reich K, Simpson E, Wollenberg A, et al. · Br J Dermatol · 2023 · Derived
    PubMed: PMID 36763879 · NCT03334435 (BREEZE-AD3) · Dermatitis, Atopic
  11. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV, Quartier P, Okamoto N, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37423231 · NCT03773978 (JUVE-BASIS) · Arthritis
  12. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.
    Piraccini BM, Ohyama M, Craiglow B, et al. · J Dermatolog Treat · 2023 · Derived
    PubMed: PMID 37381691 · NCT03570749 (BRAVE-AA1) · Alopecia Areata
  13. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
    Petri M, Bruce IN, Dörner T, et al. · Lancet · 2023 · Derived
    PubMed: PMID 36848919 · NCT03616964 (BRAVE II) · Lupus Erythematosus, Systemic
  14. The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors.
    Nurmi V, Knight C, Estcourt L, et al. · J Infect Dis · 2023 · Derived
    PubMed: PMID 36967714 · NCT02735707 (REMAP-CAP) · COVID-19
  15. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Morand EF, Vital EM, Petri M, et al. · Lancet · 2023 · Derived
    PubMed: PMID 36848918 · NCT03616912 (SLE-BRAVE I) · Lupus Erythematosus, Systemic
  16. Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.
    LOVIT-COVID Investigators, on behalf of the Canadian Critical Care Trials Group, and the REMAP-CAP Investigators, Adhikari NKJ, Hashmi M, et al. · JAMA · 2023 · Derived
    PubMed: PMID 37877585 · NCT02735707 (REMAP-CAP) · COVID-19
  17. Robust analyses for radiographic progression in rheumatoid arthritis.
    Landewé R, Sun L, Chen YF, et al. · RMD Open · 2023 · Derived
    PubMed: PMID 37015757 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  18. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
    Kwon O, Senna MM, Sinclair R, et al. · Am J Clin Dermatol · 2023 · Derived
    PubMed: PMID 36855020 · NCT03899259 (BRAVE-AA2) · Alopecia Areata
  19. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
    Ko JM, Mayo TT, Bergfeld WF, et al. · JAMA Dermatol · 2023 · Derived
    PubMed: PMID 37556146 · NCT03899259 (BRAVE-AA2) · Alopecia Areata
  20. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
    King B, Mostaghimi A, Shimomura Y, et al. · Br J Dermatol · 2023 · Derived
    PubMed: PMID 36763878 · NCT03570749 (BRAVE-AA1) · Alopecia Areata
  21. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
    Kanazawa N, Ishii T, Takita Y, et al. · Pediatr Rheumatol Online J · 2023 · Derived
    PubMed: PMID 37087470 · NCT04517253 · Aicardi-Goutieres syndrome
  22. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C, Chai KL, Piechotta V, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37162745 · NCT04381936 (RECOVERY) · COVID-19
  23. Convalescent plasma for people with COVID-19: a living systematic review.
    Iannizzi C, Chai KL, Piechotta V, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 36734509 · NCT04381936 (RECOVERY) · COVID-19
  24. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.
    Hall FC, Cheriyan J, Cope AP, et al. · Lancet Respir Med · 2023 · Derived
    PubMed: PMID 37977159 · NCT04390464 (TACTIC-R) · COVID-19
  25. Heterogeneous Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.
    Goligher EC, Lawler PR, Jensen TP, et al. · JAMA · 2023 · Derived
    PubMed: PMID 36942550 · NCT02735707 (REMAP-CAP) · COVID-19
  26. Antiplatelet agents for the treatment of adults with COVID-19.
    Fischer AL, Messer S, Riera R, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37489818 · NCT02735707 (REMAP-CAP) · COVID-19
  27. Challenges of using external data in clinical trials- an illustration in patients with COVID-19.
    Chevret S, Timsit JF, Biard L, et al. · BMC Med Res Methodol · 2023 · Derived
    PubMed: PMID 36522698 · NCT04381936 (RECOVERY) · COVID-19
  28. A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren's syndrome patients.
    Bai W, Yang F, Xu H, et al. · Trials · 2023 · Derived
    PubMed: PMID 36793118 · NCT05016297 · Sjogren's Syndrome
  29. Prevalence of musculoskeletal conditions and related disabilities in Bangladeshi adults: a cross-sectional national survey.
    Zahid-Al-Quadir A, Zaman MM, Ahmed S, et al. · BMC Rheumatol · 2023 · Background
    PubMed: PMID 33323124 · NCT06114407 · Spondylarthritis
  30. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
    Ramiro S, Nikiphorou E, Sepriano A, et al. · Ann Rheum Dis · 2023 · Background
    PubMed: PMID 36270658 · NCT06114407 · Spondylarthritis
  31. Evaluation of liver tumour response by imaging.
    Gregory J, Dioguardi Burgio M, Corrias G, et al. · JHEP Rep · 2023 · Background
    PubMed: PMID 32514496 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  32. Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation.
    Demory A, Péron JM, Calderaro J, et al. · Hepatology · 2023 · Background
    PubMed: PMID 35980227 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  33. Systemic Inflammation after Aneurysmal Subarachnoid Hemorrhage.
    Chai CZ, Ho UC, Kuo LT, et al. · Int J Mol Sci · 2023 · Background
    PubMed: PMID 37446118 · NCT06439615 (BLISS) · Pneumonia
  34. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease.
    Abhishek A, Tedeschi SK, Pascart T, et al. · Ann Rheum Dis · 2023 · Background
    PubMed: PMID 37495237 · NCT06768294 (BAPTIST) · Arthritis

2022 (43 papers)

  1. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022 · Trial result
    PubMed: PMID 33933206 · NCT04381936 (RECOVERY) · COVID-19
  2. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022 · Trial result
    PubMed: PMID 34000257 · NCT04381936 (RECOVERY) · COVID-19
  3. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet Respir Med · 2022 · Trial result
    PubMed: PMID 34672950 · NCT04381936 (RECOVERY) · COVID-19
  4. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022 · Trial result
    PubMed: PMID 35151397 · NCT04381936 (RECOVERY) · COVID-19
  5. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
    RECOVERY Collaborative Group · Lancet · 2022 · Trial result
    PubMed: PMID 35908569 · NCT04381936 (RECOVERY) · COVID-19
  6. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2022 · Trial result
    PubMed: PMID 34800427 · NCT04381936 (RECOVERY) · COVID-19
  7. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
    Phan K, Phan S, Shumack S, et al. · J Dermatolog Treat · 2022 · Trial result
    PubMed: PMID 32096671 · NCT05950542 · Vitiligo
  8. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
    Wolfe CR, Tomashek KM, Patterson TF, et al. · Lancet Respir Med · 2022 · Derived
    PubMed: PMID 35617986 · NCT04640168 · COVID-19
  9. Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
    van der Heijde D, Kartman CE, Xie L, et al. · J Rheumatol · 2022 · Derived
    PubMed: PMID 34526397 · NCT01711359 (RA-BEGIN) · Arthritis, Rheumatoid
  10. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
    Thyssen JP, Buhl T, Fernández-Peñas P, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 34275122 · NCT03733301 (BREEZE-AD7) · Dermatitis, Atopic
  11. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC, Takeuchi T, Burmester GR, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 34706874 · NCT01721044 (RA-BEACON) · Arthritis, Rheumatoid
  12. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.
    Taylor PC, Alten R, Álvaro Gracia JM, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 35264432 · NCT01711359 (RA-BEGIN) · Arthritis, Rheumatoid
  13. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
    Simpson EL, Bissonnette R, Paller AS, et al. · Br J Dermatol · 2022 · Derived
    PubMed: PMID 35442530 · NCT03435081 (BREEZE-AD5) · Dermatitis, Atopic
  14. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
    Silverberg JI, Simpson EL, Wollenberg A, et al. · JAMA Dermatol · 2022 · Derived
    PubMed: PMID 33978711 · NCT03334435 (BREEZE-AD3) · Dermatitis, Atopic
  15. Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16.
    Silverberg JI, Boguniewicz M, Waibel J, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 34846636 · NCT03435081 (BREEZE-AD5) · Dermatitis, Atopic
  16. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
    Rosmarin D, Casillas M, Chen S, et al. · J Cutan Med Surg · 2022 · Derived
    PubMed: PMID 35086348 · NCT03435081 (BREEZE-AD5) · Dermatitis, Atopic
  17. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
    REMAP-CAP Writing Committee for the REMAP-CAP Investigators, Bradbury CA, Lawler PR, et al. · JAMA · 2022 · Derived
    PubMed: PMID 35315874 · NCT02735707 (REMAP-CAP) · COVID-19
  18. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
    Reich K, DeLozier AM, Nunes FP, et al. · J Dermatolog Treat · 2022 · Derived
    PubMed: PMID 33222559 · NCT03334422 (BREEZE-AD2) · Dermatitis, Atopic
  19. Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial.
    Potter GE, Bonnett T, Rubenstein K, et al. · Ann Intern Med · 2022 · Derived
    PubMed: PMID 36442063 · NCT04640168 · COVID-19
  20. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC, Ramanan AV, de Bono S, et al. · Lancet Respir Med · 2022 · Derived
    PubMed: PMID 34480861 · NCT04421027 (COV-BARRIER) · COVID-19
  21. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A, Prinz C, Fichtner F, et al. · Cochrane Database Syst Rev · 2022 · Derived
    PubMed: PMID 35695334 · NCT04381936 (RECOVERY) · COVID-19
  22. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.
    Koster MJ, Crowson CS, Giblon RE, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 35190385 · NCT03026504 · Giant Cell Arteritis
  23. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
    King B, Ohyama M, Kwon O, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 35334197 · NCT03570749 (BRAVE-AA1) · Alopecia Areata
  24. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
    Kim H, Dill S, O'Brien M, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 32843325 · NCT01724580 · Dermatomyositis
  25. Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials.
    Katoh N, Takita Y, Isaka Y, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 36255569 · NCT03334422 (BREEZE-AD2) · Dermatitis, Atopic
  26. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.
    Hirsch C, Park YS, Piechotta V, et al. · Cochrane Database Syst Rev · 2022 · Derived
    PubMed: PMID 35713300 · NCT04381936 (RECOVERY) · COVID-19
  27. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
    Ely EW, Ramanan AV, Kartman CE, et al. · Lancet Respir Med · 2022 · Derived
    PubMed: PMID 35123660 · NCT04421027 (COV-BARRIER) · COVID-19
  28. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.
    Dörner T, van Vollenhoven RF, Doria A, et al. · Arthritis Res Ther · 2022 · Derived
    PubMed: PMID 35578304 · NCT02708095 · Lupus Erythematosus, Systemic
  29. Hematologic abnormalities in Aicardi Goutières Syndrome.
    Adang LA, Gavazzi F, D'Aiello R, et al. · Mol Genet Metab · 2022 · Derived
    PubMed: PMID 35786528 · NCT03921554 · Aicardi-Goutieres syndrome
  30. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    Ytterberg SR, Bhatt DL, Mikuls TR, et al. · N Engl J Med · 2022 · Background
    PubMed: PMID 35081280 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  31. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H, Jia H, Xia T, et al. · Dermatol Ther · 2022 · Background
    PubMed: PMID 35703351 · NCT05969730 · Dermatitis, Atopic
  32. Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial.
    Waibel M, Thomas HE, Wentworth JM, et al. · Trials · 2022 · Background
    PubMed: PMID 35606820 · NCT04774224 (BANDIT) · Diabetes Mellitus, Type 1
  33. The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights.
    Toussirot E · Pharmaceuticals (Basel) · 2022 · Background
    PubMed: PMID 35337068 · NCT06114407 · Spondylarthritis
  34. Benign liver tumours: understanding molecular physiology to adapt clinical management.
    Nault JC, Paradis V, Ronot M, et al. · Nat Rev Gastroenterol Hepatol · 2022 · Background
    PubMed: PMID 35835851 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  35. Baricitinib in Alopecia Areata.
    Messenger A, Harries M · N Engl J Med · 2022 · Background
    PubMed: PMID 35507486 · NCT06065046 · Brain Injuries, Traumatic
  36. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
    Lobo PB, Guisado-Hernández P, Villaoslada I, et al. · J Clin Immunol · 2022 · Background
    PubMed: PMID 35507130 · NCT07262983 · Dermatitis, Atopic
  37. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy.
    Lio PA, Simpson EL, Han G, et al. · J Dermatolog Treat · 2022 · Background
    PubMed: PMID 34176407 · NCT05969730 · Dermatitis, Atopic
  38. Abrocitinib Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway.
    Li T, Li L, Peng R, et al. · Cells · 2022 · Background
    PubMed: PMID 36429017 · NCT06065046 · Brain Injuries, Traumatic
  39. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
    Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. · Ann Rheum Dis · 2022 · Background
    PubMed: PMID 33906853 · NCT06114407 · Spondylarthritis
  40. The use of azathioprine in atopic dermatitis: A review.
    Bracho-Borro M, Franco-Ruiz PA, Magaña M, et al. · Dermatol Ther · 2022 · Background
    PubMed: PMID 35751547 · NCT05969730 · Dermatitis, Atopic
  41. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
    Bieber T, Reich K, Paul C, et al. · Br J Dermatol · 2022 · Background
    PubMed: PMID 35484697 · NCT05969730 · Dermatitis, Atopic
  42. Clinico-Epidemiological Profile of Childhood Alopecia Areata Along with Dermoscopic Correlation: A Cross-Section, Observational Study.
    Bhardwaj P, Basu D, Podder I, et al. · Indian Dermatol Online J · 2022 · Background
    PubMed: PMID 33959521 · NCT06545110 · Alopecia Areata
  43. Genetic predisposition of alopecia areata in jordanians: A case-control study.
    Al-Eitan LN, Alghamdi MA, Al Momani RO, et al. · Heliyon · 2022 · Background
    PubMed: PMID 35392398 · NCT06545110 · Alopecia Areata

2021 (48 papers)

  1. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
    WHO Solidarity Trial Consortium, Pan H, Peto R, et al. · N Engl J Med · 2021 · Trial result
    PubMed: PMID 33264556 · NCT04970719 · COVID-19
  2. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.
    Singh AK, Singh R, Joshi SR, et al. · Diabetes Metab Syndr · 2021 · Trial result
    PubMed: PMID 34192610 · NCT04970719 · COVID-19
  3. Dexamethasone in Hospitalized Patients with Covid-19.
    RECOVERY Collaborative Group, Horby P, Lim WS, et al. · N Engl J Med · 2021 · Trial result
    PubMed: PMID 32678530 · NCT04381936 (RECOVERY) · COVID-19
  4. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2021 · Trial result
    PubMed: PMID 33031764 · NCT04381936 (RECOVERY) · COVID-19
  5. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group · Lancet · 2021 · Trial result
    PubMed: PMID 33545096 · NCT04381936 (RECOVERY) · COVID-19
  6. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
    Kalil AC, Patterson TF, Mehta AK, et al. · N Engl J Med · 2021 · Trial result
    PubMed: PMID 33306283 · NCT04970719 · COVID-19
  7. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
    Guimarães PO, Quirk D, Furtado RH, et al. · N Engl J Med · 2021 · Trial result
    PubMed: PMID 34133856 · NCT04970719 · COVID-19
  8. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic's Impact in Type 1 and Type 2 Diabetes.
    Gregory JM, Slaughter JC, Duffus SH, et al. · Diabetes Care · 2021 · Trial result
    PubMed: PMID 33268335 · NCT04970719 · COVID-19
  9. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
    Garibaldi BT, Wang K, Robinson ML, et al. · JAMA Netw Open · 2021 · Trial result
    PubMed: PMID 33760094 · NCT04970719 · COVID-19
  10. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
    Chen CX, Wang JJ, Li H, et al. · Leukemia · 2021 · Trial result
    PubMed: PMID 33990684 · NCT04970719 · COVID-19
  11. Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE.
    Yang Y, Li XF, Zhang X, et al. · Rheumatol Ther · 2021 · Derived
    PubMed: PMID 32876903 · NCT02265705 · Arthritis, Rheumatoid
  12. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
    Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, et al. · JAMA · 2021 · Derived
    PubMed: PMID 34606578 · NCT02735707 (REMAP-CAP) · COVID-19
  13. Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations.
    UPMC REMAP-COVID Group, on behalf of the REMAP-CAP Investigators · Trials · 2021 · Derived
    PubMed: PMID 33509275 · NCT02735707 (REMAP-CAP) · COVID-19
  14. Research Priorities for U.K. Pediatric Critical Care in 2019: Healthcare Professionals' and Parents' Perspectives.
    Tume LN, Menzies JC, Ray S, et al. · Pediatr Crit Care Med · 2021 · Derived
    PubMed: PMID 33394942 · NCT02735707 (REMAP-CAP) · COVID-19
  15. The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
    Thudium CS, Bay-Jensen AC, Cahya S, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 33046136 · NCT01721057 (RA-BUILD) · Arthritis, Rheumatoid
  16. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
    Silverberg JI, DeLozier A, Sun L, et al. · Health Qual Life Outcomes · 2021 · Derived
    PubMed: PMID 34688290 · NCT03334422 (BREEZE-AD2) · Dermatitis, Atopic
  17. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
    REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33631065 · NCT02735707 (REMAP-CAP) · COVID-19
  18. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
    REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 34351722 · NCT02735707 (REMAP-CAP) · COVID-19
  19. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Reich K, Kabashima K, Peris K, et al. · JAMA Dermatol · 2021 · Derived
    PubMed: PMID 33001140 · NCT03733301 (BREEZE-AD7) · Dermatitis, Atopic
  20. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
    Ramanan AV, Guly CM, Keller SY, et al. · Trials · 2021 · Derived
    PubMed: PMID 34627340 · NCT04088409 · Uveitis
  21. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V, Iannizzi C, Chai KL, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34013969 · NCT04381936 (RECOVERY) · COVID-19
  22. Colchicine for the treatment of COVID-19.
    Mikolajewska A, Fischer AL, Piechotta V, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34658014 · NCT04381936 (RECOVERY) · COVID-19
  23. Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
    Li ZG, Hu JK, Li XP, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 33237533 · NCT02265705 · Arthritis, Rheumatoid
  24. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N, Hirsch C, Chai KL, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34473343 · NCT04390464 (TACTIC-R) · COVID-19
  25. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B, Maari C, Lain E, et al. · Am J Clin Dermatol · 2021 · Derived
    PubMed: PMID 33826132 · NCT03334396 (BREEZE-AD1) · Dermatitis, Atopic
  26. Interventions for cutaneous disease in systemic lupus erythematosus.
    Hannon CW, McCourt C, Lima HC, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 33687069 · NCT02708095 · Lupus Erythematosus, Systemic
  27. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
    Emery P, Tanaka Y, Cardillo T, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 32414425 · NCT01721044 (RA-BEACON) · Arthritis, Rheumatoid
  28. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies.
    Buhl T, Rosmarin D, Serra-Baldrich E, et al. · Dermatol Ther (Heidelb) · 2021 · Derived
    PubMed: PMID 33899152 · NCT03334422 (BREEZE-AD2) · Dermatitis, Atopic
  29. COVID-19 and Solid Organ Transplantation: A Review Article.
    Azzi Y, Bartash R, Scalea J, et al. · Transplantation · 2021 · Derived
    PubMed: PMID 33148977 · NCT04401579 · COVID-19
  30. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
    ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 34351721 · NCT02735707 (REMAP-CAP) · COVID-19
  31. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
    Arabi YM, Gordon AC, Derde LPG, et al. · Intensive Care Med · 2021 · Derived
    PubMed: PMID 34251506 · NCT02735707 (REMAP-CAP) · COVID-19
  32. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
    Wollenberg A, Nakahara T, Maari C, et al. · J Eur Acad Dermatol Venereol · 2021 · Background
    PubMed: PMID 33834521 · NCT05969730 · Dermatitis, Atopic
  33. Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course.
    van Rosmalen BV, Furumaya A, Klompenhouwer AJ, et al. · Liver Int · 2021 · Background
    PubMed: PMID 34155783 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  34. EULAR recommendations for intra-articular therapies.
    Uson J, Rodriguez-García SC, Castellanos-Moreira R, et al. · Ann Rheum Dis · 2021 · Background
    PubMed: PMID 34035002 · NCT06768294 (BAPTIST) · Arthritis
  35. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
    Simpson EL, Lacour JP, Spelman L, et al. · Br J Dermatol · 2021 · Background
    PubMed: PMID 31995838 · NCT05969730 · Dermatitis, Atopic
  36. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.
    Silverberg JI, Lei D, Yousaf M, et al. · Br J Dermatol · 2021 · Background
    PubMed: PMID 32959390 · NCT05969730 · Dermatitis, Atopic
  37. Genome-encoded cytoplasmic double-stranded RNAs, found in C9ORF72 ALS-FTD brain, propagate neuronal loss.
    Rodriguez S, Sahin A, Schrank BR, et al. · Sci Transl Med · 2021 · Background
    PubMed: PMID 34233951 · NCT05189106 (NADALS) · Alzheimer Disease
  38. Machine learning identifies candidates for drug repurposing in Alzheimer's disease.
    Rodriguez S, Hug C, Todorov P, et al. · Nat Commun · 2021 · Background
    PubMed: PMID 33589615 · NCT05189106 (NADALS) · Alzheimer Disease
  39. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.
    Poussin K, Pilati C, Couchy G, et al. · Oncoimmunology · 2021 · Background
    PubMed: PMID 24501689 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  40. Current and future status of JAK inhibitors.
    McLornan DP, Pope JE, Gotlib J, et al. · Lancet · 2021 · Background
    PubMed: PMID 34454676 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  41. 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018.
    Mammen AL, Allenbach Y, Stenzel W, et al. · Neuromuscul Disord · 2021 · Background
    PubMed: PMID 31791867 · NCT05524311 (MYOCIT) · Dermatomyositis
  42. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.
    Hasni SA, Gupta S, Davis M, et al. · Nat Commun · 2021 · Background
    PubMed: PMID 34099646 · NCT07262983 · Dermatitis, Atopic
  43. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.
    Goletti D, Cantini F · N Engl J Med · 2021 · Background
    PubMed: PMID 33657299 · NCT04970719 · COVID-19
  44. Lupus-like autoimmunity and increased interferon response in patients with STAT3-deficient hyper-IgE syndrome.
    Goel RR, Nakabo S, Dizon BLP, et al. · J Allergy Clin Immunol · 2021 · Background
    PubMed: PMID 32768442 · NCT07262983 · Dermatitis, Atopic
  45. Effect of PTPN22, FAS/FASL, IL2RA and CTLA4 genetic polymorphisms on the risk of developing alopecia areata: A systematic review of the literature and meta-analysis.
    Gil-Quiñones SR, Sepúlveda-Pachón IT, Sánchez Vanegas G, et al. · PLoS One · 2021 · Background
    PubMed: PMID 34735462 · NCT06545110 · Alopecia Areata
  46. Treatment of severe lichen planus with the JAK inhibitor tofacitinib.
    Damsky W, Wang A, Olamiju B, et al. · J Allergy Clin Immunol · 2021 · Background
    PubMed: PMID 32018031 · NCT06158113 · Lichen Planus
  47. Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas.
    Bayard Q, Caruso S, Couchy G, et al. · Gut · 2021 · Background
    PubMed: PMID 31907296 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  48. Development of a Bangla version of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Bath Ankylosing Spondylitis Functional Index (BASFI).
    Abdal SJ, Yesmin S, Shazzad MN, et al. · Int J Rheum Dis · 2021 · Background
    PubMed: PMID 33135389 · NCT06114407 · Spondylarthritis

2020 (37 papers)

  1. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y, Zhang D, Du G, et al. · Lancet · 2020 · Trial result
    PubMed: PMID 32423584 · NCT04970719 · COVID-19
  2. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study.
    Wang S, Ma P, Zhang S, et al. · Diabetologia · 2020 · Trial result
    PubMed: PMID 32647915 · NCT04970719 · COVID-19
  3. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD, Gottlieb RL, Criner GJ, et al. · JAMA · 2020 · Trial result
    PubMed: PMID 32821939 · NCT04970719 · COVID-19
  4. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
    Richardson P, Griffin I, Tucker C, et al. · Lancet · 2020 · Trial result
    PubMed: PMID 32032529 · NCT04393051 (BARICIVID-19) · COVID-19
  5. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
    RECOVERY Collaborative Group, Horby P, Mafham M, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 33031652 · NCT04381936 (RECOVERY) · COVID-19
  6. Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis.
    Ortolan A, Lorenzin M, Felicetti M, et al. · Int J Infect Dis · 2020 · Trial result
    PubMed: PMID 32800858 · NCT04970719 · COVID-19
  7. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties.
    Matthay MA, Thompson BT · Lancet Respir Med · 2020 · Trial result
    PubMed: PMID 33129421 · NCT04970719 · COVID-19
  8. Baricitinib for COVID-19: a suitable treatment?
    Favalli EG, Biggioggero M, Maioli G, et al. · Lancet Infect Dis · 2020 · Trial result
    PubMed: PMID 32251638 · NCT04393051 (BARICIVID-19) · COVID-19
  9. Remdesivir for the Treatment of Covid-19 - Final Report.
    Beigel JH, Tomashek KM, Dodd LE, et al. · N Engl J Med · 2020 · Trial result
    PubMed: PMID 32445440 · NCT04970719 · COVID-19
  10. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.
    Winthrop KL, Bingham CO, Komocsar WJ, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 30999933 · NCT01885078 (RA-BEYOND) · Arthritis, Rheumatoid
  11. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
    Wells AF, Greenwald M, Bradley JD, et al. · Rheumatol Ther · 2020 · Derived
    PubMed: PMID 29680881 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  12. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
    Tanaka Y, Fautrel B, Keystone EC, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 31040122 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  13. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
    Smolen JS, Genovese MC, Takeuchi T, et al. · J Rheumatol · 2020 · Derived
    PubMed: PMID 30219772 · NCT01885078 (RA-BEYOND) · Arthritis, Rheumatoid
  14. Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial.
    Michaud K, Pope JE, Emery P, et al. · Rheumatol Ther · 2020 · Derived
    PubMed: PMID 31228100 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  15. Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial.
    Kulkarni S, Fisk M, Kostapanos M, et al. · Trials · 2020 · Derived
    PubMed: PMID 32641154 · NCT04390464 (TACTIC-R) · COVID-19
  16. Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.
    Fleischmann R, Takeuchi T, Schiff M, et al. · Arthritis Care Res (Hoboken) · 2020 · Derived
    PubMed: PMID 31233281 · NCT01711359 (RA-BEGIN) · Arthritis, Rheumatoid
  17. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib.
    Combe B, Balsa A, Sarzi-Puttini P, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 30842122 · NCT01721057 (RA-BUILD) · Arthritis, Rheumatoid
  18. Old and new antirheumatic drugs for the treatment of COVID-19.
    Benucci M, Damiani A, Infantino M, et al. · Joint Bone Spine · 2020 · Derived
    PubMed: PMID 32321635 · NCT04320277 (BARI-COVID) · COVID-19
  19. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
    Angus DC, Derde L, Al-Beidh F, et al. · JAMA · 2020 · Derived
    PubMed: PMID 32876697 · NCT02735707 (REMAP-CAP) · COVID-19
  20. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.
    Angus DC, Berry S, Lewis RJ, et al. · Ann Am Thorac Soc · 2020 · Derived
    PubMed: PMID 32267771 · NCT02735707 (REMAP-CAP) · COVID-19
  21. A Novel Coronavirus from Patients with Pneumonia in China, 2019.
    Zhu N, Zhang D, Wang W, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 31978945 · NCT04320277 (BARI-COVID) · COVID-19
  22. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
    Zhou F, Yu T, Du R, et al. · Lancet · 2020 · Background
    PubMed: PMID 32171076 · NCT04320277 (BARI-COVID) · COVID-19
  23. Meaningful improvement thresholds in measures of pain and quality of life in oral lichen planus.
    Wiriyakijja P, Porter S, Fedele S, et al. · Oral Dis · 2020 · Background
    PubMed: PMID 32363637 · NCT06158113 · Lichen Planus
  24. Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up.
    Vernuccio F, Ronot M, Dioguardi Burgio M, et al. · Radiology · 2020 · Background
    PubMed: PMID 32181728 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  25. COVID-19: combining antiviral and anti-inflammatory treatments.
    Stebbing J, Phelan A, Griffin I, et al. · Lancet Infect Dis · 2020 · Background
    PubMed: PMID 32113509 · NCT04320277 (BARI-COVID) · COVID-19
  26. The National Early Warning Score 2 (NEWS2).
    Smith GB, Redfern OC, Pimentel MA, et al. · Clin Med (Lond) · 2020 · Background
    PubMed: PMID 31092526 · NCT04970719 · COVID-19
  27. IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus.
    Shao S, Tsoi LC, Sarkar MK, et al. · Sci Transl Med · 2020 · Background
    PubMed: PMID 31554739 · NCT06158113 · Lichen Planus
  28. Tofacitinib for the Treatment of Pyoderma Gangrenosum.
    Kochar B, Herfarth N, Mamie C, et al. · Clin Gastroenterol Hepatol · 2020 · Background
    PubMed: PMID 30404036 · NCT04901325 · Skin Diseases
  29. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
    Jorgensen SCJ, Tse CLY, Burry L, et al. · Pharmacotherapy · 2020 · Background
    PubMed: PMID 32542785 · NCT06065046 · Brain Injuries, Traumatic
  30. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
    Huang C, Wang Y, Li X, et al. · Lancet · 2020 · Background
    PubMed: PMID 31986264 · NCT04320277 (BARI-COVID) · COVID-19
  31. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
    Gross AM, Wolters PL, Dombi E, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32187457 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  32. Chloroquine and hydroxychloroquine in covid-19.
    Ferner RE, Aronson JK · BMJ · 2020 · Background
    PubMed: PMID 32269046 · NCT04358614 · COVID-19
  33. WHO Declares COVID-19 a Pandemic.
    Cucinotta D, Vanelli M · Acta Biomed · 2020 · Background
    PubMed: PMID 32191675 · NCT04970719 · COVID-19
  34. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
    Cao B, Wang Y, Wen D, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32187464 · NCT04320277 (BARI-COVID) · COVID-19
  35. Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis.
    Begemann M, Leon M, van der Horn HJ, et al. · Sci Rep · 2020 · Background
    PubMed: PMID 32999392 · NCT06065046 · Brain Injuries, Traumatic
  36. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
    Bechman K, Subesinghe S, Norton S, et al. · Rheumatology (Oxford) · 2020 · Background
    PubMed: PMID 30982883 · NCT04320277 (BARI-COVID) · COVID-19
  37. Sex, gender and COVID-19: a call to action.
    Ahmed SB, Dumanski SM · Can J Public Health · 2020 · Background
    PubMed: PMID 32990927 · NCT04970719 · COVID-19

2019 (15 papers)

  1. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
    Taylor PC, Kremer JM, Emery P, et al. · Ann Rheum Dis · 2019 · Derived
    PubMed: PMID 29463520 · NCT01885078 (RA-BEYOND) · Arthritis, Rheumatoid
  2. Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.
    Tanaka Y, McInnes IB, Taylor PC, et al. · Arthritis Rheumatol · 2019 · Derived
    PubMed: PMID 30058112 · NCT01885078 (RA-BEYOND) · Arthritis, Rheumatoid
  3. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
    Sanchez GAM, Reinhardt A, Ramsey S, et al. · J Clin Invest · 2019 · Derived
    PubMed: PMID 29649002 · NCT01724580 · Dermatomyositis
  4. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
    Kim H, Brooks KM, Tang CC, et al. · Clin Pharmacol Ther · 2019 · Derived
    PubMed: PMID 29134648 · NCT01724580 · Dermatomyositis
  5. Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
    Bingham CO, Gaich CL, DeLozier AM, et al. · Trials · 2019 · Derived
    PubMed: PMID 30902094 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  6. Corrigendum: Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.
    Wollenberg A, Szepietowski J, Taieb A, et al. · J Eur Acad Dermatol Venereol · 2019 · Background
    PubMed: PMID 31259446 · NCT05969730 · Dermatitis, Atopic
  7. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
    Veale DJ, McGonagle D, McInnes IB, et al. · Rheumatology (Oxford) · 2019 · Background
    PubMed: PMID 29618084 · NCT06114407 · Spondylarthritis
  8. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 2: reliability and application to multiple joints of a standardised consensus-based scoring system.
    Terslev L, Naredo E, Aegerter P, et al. · RMD Open · 2019 · Background
    PubMed: PMID 28948984 · NCT06768294 (BAPTIST) · Arthritis
  9. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
    T Virtanen A, Haikarainen T, Raivola J, et al. · BioDrugs · 2019 · Background
    PubMed: PMID 30701418 · NCT06768294 (BAPTIST) · Arthritis
  10. Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum.
    Ortega-Loayza AG, Nugent WH, Lucero OM, et al. · Br J Dermatol · 2019 · Background
    PubMed: PMID 28734003 · NCT04901325 · Skin Diseases
  11. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor.
    Nasifoglu S, Heinrich B, Welzel J, et al. · Br J Dermatol · 2019 · Background
    PubMed: PMID 29451690 · NCT04901325 · Skin Diseases
  12. Tracking JAKs in spondyloarthritis: rationale and expectations.
    Miceli-Richard C, Dougados M · Ann Rheum Dis · 2019 · Background
    PubMed: PMID 28314752 · NCT06114407 · Spondylarthritis
  13. The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.
    Giancane G, Lavarello C, Pistorio A, et al. · Pediatr Rheumatol Online J · 2019 · Background
    PubMed: PMID 31118099 · NCT05524311 (MYOCIT) · Dermatomyositis
  14. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial.
    Gerbens LAA, Hamann SAS, Brouwer MWD, et al. · Br J Dermatol · 2019 · Background
    PubMed: PMID 29237228 · NCT05969730 · Dermatitis, Atopic
  15. Epidemiology of atopic dermatitis in adults: Results from an international survey.
    Barbarot S, Auziere S, Gadkari A, et al. · Allergy · 2019 · Background
    PubMed: PMID 29319189 · NCT05969730 · Dermatitis, Atopic

2018 (8 papers)

  1. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Wallace DJ, Furie RA, Tanaka Y, et al. · Lancet · 2018 · Derived
    PubMed: PMID 30043749 · NCT02708095 · Lupus Erythematosus, Systemic
  2. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.
    Tanaka Y, Ishii T, Cai Z, et al. · Mod Rheumatol · 2018 · Derived
    PubMed: PMID 28440680 · NCT01469013 · Arthritis, Rheumatoid
  3. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M, Takeuchi T, Fleischmann R, et al. · Arthritis Res Ther · 2018 · Derived
    PubMed: PMID 28923098 · NCT01711359 (RA-BEGIN) · Arthritis, Rheumatoid
  4. Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis.
    Genovese MC, Kremer JM, Kartman CE, et al. · Rheumatology (Oxford) · 2018 · Derived
    PubMed: PMID 29415145 · NCT01721044 (RA-BEACON) · Arthritis, Rheumatoid
  5. Alopecia areata.
    Pratt CH, King LE, Messenger AG, et al. · Nat Rev Dis Primers · 2018 · Background
    PubMed: PMID 28300084 · NCT06545110 · Alopecia Areata
  6. Adaptation of Chinese and English versions of the Ankylosing Spondylitis quality of life (ASQoL) scale for use in Singapore.
    Leung YY, Lee W, Lui NL, et al. · BMC Musculoskelet Disord · 2018 · Background
    PubMed: PMID 28818056 · NCT06114407 · Spondylarthritis
  7. EASL Clinical Practice Guidelines on the management of benign liver tumours.
    European Association for the Study of the Liver (EASL) · J Hepatol · 2018 · Background
    PubMed: PMID 27085809 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  8. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.
    Channappanavar R, Perlman S · Semin Immunopathol · 2018 · Background
    PubMed: PMID 28466096 · NCT04320277 (BARI-COVID) · COVID-19

2017 (9 papers)

  1. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
    Fleischmann R, Schiff M, van der Heijde D, et al. · Arthritis Rheumatol · 2017 · Trial result
    PubMed: PMID 27723271 · NCT05660655 · Arthritis, Rheumatoid
  2. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
    Dougados M, van der Heijde D, Chen YC, et al. · Ann Rheum Dis · 2017 · Trial result
    PubMed: PMID 27689735 · NCT05660655 · Arthritis, Rheumatoid
  3. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC, Keystone EC, van der Heijde D, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 28199814 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  4. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
    Smolen JS, Kremer JM, Gaich CL, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27799159 · NCT01721044 (RA-BEACON) · Arthritis, Rheumatoid
  5. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC, Taylor PC, Tanaka Y, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 28798049 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  6. Janus kinase inhibitors for rheumatoid arthritis.
    Yamaoka K · Curr Opin Chem Biol · 2017 · Background
    PubMed: PMID 26994322 · NCT05827497 · Arthritis, Rheumatoid
  7. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
    Nault JC, Couchy G, Balabaud C, et al. · Gastroenterology · 2017 · Background
    PubMed: PMID 27939373 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  8. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.
    Baraliakos X, Kiltz U, Peters S, et al. · Rheumatology (Oxford) · 2017 · Background
    PubMed: PMID 27997346 · NCT06114407 · Spondylarthritis
  9. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
    Alves de Medeiros AK, Speeckaert R, Desmet E, et al. · PLoS One · 2017 · Background
    PubMed: PMID 27711196 · NCT04901325 · Skin Diseases

2016 (3 papers)

  1. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
    Tanaka Y, Emoto K, Cai Z, et al. · J Rheumatol · 2016 · Derived
    PubMed: PMID 26834213 · NCT01469013 · Arthritis, Rheumatoid
  2. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
    Genovese MC, Kremer J, Zamani O, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27028914 · NCT01721044 (RA-BEACON) · Arthritis, Rheumatoid
  3. Diagnostic accuracy of ultrasound, conventional radiography and synovial fluid analysis in the diagnosis of calcium pyrophosphate dihydrate crystal deposition disease.
    Filippou G, Adinolfi A, Cimmino MA, et al. · Clin Exp Rheumatol · 2016 · Background
    PubMed: PMID 26886247 · NCT06768294 (BAPTIST) · Arthritis

2015 (3 papers)

  1. Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort.
    Machado P, Navarro-Compán V, Landewé R, et al. · Arthritis Rheumatol · 2015 · Background
    PubMed: PMID 25332195 · NCT06114407 · Spondylarthritis
  2. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients.
    Kelly S, Humby F, Filer A, et al. · Ann Rheum Dis · 2015 · Background
    PubMed: PMID 24336336 · NCT06768294 (BAPTIST) · Arthritis
  3. Pathophysiology of pyoderma gangrenosum (PG): an updated review.
    Braswell SF, Kostopoulos TC, Ortega-Loayza AG, et al. · J Am Acad Dermatol · 2015 · Background
    PubMed: PMID 26253362 · NCT04901325 · Skin Diseases

2014 (5 papers)

  1. Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond.
    Smith JA, Colbert RA · Arthritis Rheumatol · 2014 · Background
    PubMed: PMID 24504793 · NCT06114407 · Spondylarthritis
  2. Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi(®)).
    Shanmugam VK, McNish S, Shara N, et al. · J Foot Ankle Surg · 2014 · Background
    PubMed: PMID 23953278 · NCT04901325 · Skin Diseases
  3. Cross-cultural adaptation and validation of a Bengali Health Assessment Questionnaire for use in rheumatoid arthritis patients.
    Islam N, Baron Basak T, OudeVoshaar MA, et al. · Int J Rheum Dis · 2014 · Background
    PubMed: PMID 23992261 · NCT05827497 · Arthritis, Rheumatoid
  4. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.
    Eichenfield LF, Tom WL, Chamlin SL, et al. · J Am Acad Dermatol · 2014 · Background
    PubMed: PMID 24290431 · NCT05969730 · Dermatitis, Atopic
  5. Neuroprotective effect of AG490 in experimental traumatic brain injury of rats.
    DU AL, Ji TL, Yang B, et al. · Chin Med J (Engl) · 2014 · Background
    PubMed: PMID 23924471 · NCT06065046 · Brain Injuries, Traumatic

2013 (3 papers)

  1. Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation.
    Palanivel JA, Macbeth AE, Levell NJ, et al. · Clin Exp Dermatol · 2013 · Background
    PubMed: PMID 22607468 · NCT04901325 · Skin Diseases
  2. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy.
    Liu D, Ahmet A, Ward L, et al. · Allergy Asthma Clin Immunol · 2013 · Background
    PubMed: PMID 23947590 · NCT04901325 · Skin Diseases
  3. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis.
    Lazarevic D, Pistorio A, Palmisani E, et al. · Ann Rheum Dis · 2013 · Background
    PubMed: PMID 22736096 · NCT05524311 (MYOCIT) · Dermatomyositis

2012 (1 paper)

  1. How to calculate sample size in randomized controlled trial?
    Zhong B · J Thorac Dis · 2012 · Trial result
    PubMed: PMID 22263004 · NCT04970719 · COVID-19

2011 (2 papers)

  1. EULAR recommendations for calcium pyrophosphate deposition. Part II: management.
    Zhang W, Doherty M, Pascual E, et al. · Ann Rheum Dis · 2011 · Background
    PubMed: PMID 21257614 · NCT06768294 (BAPTIST) · Arthritis
  2. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.
    Machado P, Landewé R, Lie E, et al. · Ann Rheum Dis · 2011 · Background
    PubMed: PMID 21068095 · NCT06114407 · Spondylarthritis

2009 (6 papers)

  1. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
    Von Hoff DD, LoRusso PM, Rudin CM, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19726763 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  2. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis.
    Sieper J, Rudwaleit M, Baraliakos X, et al. · Ann Rheum Dis · 2009 · Background
    PubMed: PMID 19433414 · NCT06114407 · Spondylarthritis
  3. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.
    Rudwaleit M, van der Heijde D, Landewé R, et al. · Ann Rheum Dis · 2009 · Background
    PubMed: PMID 19297344 · NCT06114407 · Spondylarthritis
  4. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
    Rebouissou S, Amessou M, Couchy G, et al. · Nature · 2009 · Background
    PubMed: PMID 19020503 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  5. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas.
    Dokmak S, Paradis V, Vilgrain V, et al. · Gastroenterology · 2009 · Background
    PubMed: PMID 19664629 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  6. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience.
    Bioulac-Sage P, Laumonier H, Couchy G, et al. · Hepatology · 2009 · Background
    PubMed: PMID 19585623 · NCT06490757 (JAKIH) · Adenoma, Liver Cell

2008 (2 papers)

  1. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study.
    Ruperto N, Ravelli A, Pistorio A, et al. · Arthritis Rheum · 2008 · Background
    PubMed: PMID 18163404 · NCT05524311 (MYOCIT) · Dermatomyositis
  2. A scoring system for mucosal disease severity with special reference to oral lichen planus.
    Escudier M, Ahmed N, Shirlaw P, et al. · Br J Dermatol · 2008 · Background
    PubMed: PMID 17711534 · NCT06158113 · Lichen Planus

2007 (1 paper)

  1. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.
    Bioulac-Sage P, Rebouissou S, Thomas C, et al. · Hepatology · 2007 · Background
    PubMed: PMID 17663417 · NCT06490757 (JAKIH) · Adenoma, Liver Cell

2006 (5 papers)

  1. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.
    Zucman-Rossi J, Jeannot E, Nhieu JT, et al. · Hepatology · 2006 · Background
    PubMed: PMID 16496320 · NCT06490757 (JAKIH) · Adenoma, Liver Cell
  2. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial.
    Meggitt SJ, Gray JC, Reynolds NJ, et al. · Lancet · 2006 · Background
    PubMed: PMID 16530578 · NCT05969730 · Dermatitis, Atopic
  3. Gout-associated uric acid crystals activate the NALP3 inflammasome.
    Martinon F, Pétrilli V, Mayor A, et al. · Nature · 2006 · Background
    PubMed: PMID 16407889 · NCT06768294 (BAPTIST) · Arthritis
  4. Synovitis score: discrimination between chronic low-grade and high-grade synovitis.
    Krenn V, Morawietz L, Burmester GR, et al. · Histopathology · 2006 · Background
    PubMed: PMID 16978198 · NCT06768294 (BAPTIST) · Arthritis
  5. Acute lung injury in patients with subarachnoid hemorrhage: incidence, risk factors, and outcome.
    Kahn JM, Caldwell EC, Deem S, et al. · Crit Care Med · 2006 · Background
    PubMed: PMID 16374174 · NCT06439615 (BLISS) · Pneumonia

2003 (2 papers)

  1. Transforming growth factor-beta levels in synovial fluid of osteoarthritis with or without calcium pyrophosphate dihydrate crystals.
    Punzi L, Oliviero F, Ramonda R, et al. · J Rheumatol · 2003 · Background
    PubMed: PMID 12583352 · NCT06768294 (BAPTIST) · Arthritis
  2. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence.
    Bode RK, Klein-Gitelman MS, Miller ML, et al. · Arthritis Rheum · 2003 · Background
    PubMed: PMID 12579588 · NCT05524311 (MYOCIT) · Dermatomyositis

2002 (4 papers)

  1. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression.
    Murphy LA, Atherton D · Br J Dermatol · 2002 · Background
    PubMed: PMID 12174104 · NCT05969730 · Dermatitis, Atopic
  2. Pulmonary and cardiac sequelae of subarachnoid haemorrhage: time for active management?
    Macmillan CS, Grant IS, Andrews PJ, et al. · Intensive Care Med · 2002 · Background
    PubMed: PMID 12185419 · NCT06439615 (BLISS) · Pneumonia
  3. Grading of chronic synovitis--a histopathological grading system for molecular and diagnostic pathology.
    Krenn V, Morawietz L, Häupl T, et al. · Pathol Res Pract · 2002 · Background
    PubMed: PMID 12092767 · NCT06768294 (BAPTIST) · Arthritis
  4. Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis.
    Conner SD, Schmid SL · J Cell Biol · 2002 · Background
    PubMed: PMID 11877461 · NCT04358614 · COVID-19

2001 (1 paper)

  1. Validation of a modified Early Warning Score in medical admissions.
    Subbe CP, Kruger M, Rutherford P, et al. · QJM · 2001 · Background
    PubMed: PMID 11588210 · NCT04358614 · COVID-19

1994 (1 paper)

  1. Measurement of health status in children with juvenile rheumatoid arthritis.
    Singh G, Athreya BH, Fries JF, et al. · Arthritis Rheum · 1994 · Background
    PubMed: PMID 7986222 · NCT05524311 (MYOCIT) · Dermatomyositis

1989 (1 paper)

  1. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes.
    Guerne PA, Terkeltaub R, Zuraw B, et al. · Arthritis Rheum · 1989 · Background
    PubMed: PMID 2554932 · NCT06768294 (BAPTIST) · Arthritis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).